The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The mechanism of action and benefits of KLN-1010, an in vivo CAR T-cell therapy, for R/R myeloma
P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Royal Prince Alfred Hospital & University of Sydney, Sydney, Australia, discusses the mechanism of action and rationale for the use of KLN-1010 in relapsed/refractory (R/R) multiple myeloma (MM). KLN-1010 is an in vivo CAR T-cell therapy that utilizes a modified lentiviral vector to deliver an anti-BCMA CAR to T-cells, allowing for production of CAR T-cells directly in the body. Prof. Ho highlights that this approach is off-the-shelf, reduces logistical burden, and may expand access to CAR-T, while also potentially resulting in fitter, less exhausted T-cells. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
KLN-1010 is an in-vivo CAR-T, which basically utilizes the injection of a modified lentiviral vector, which has a modified envelope. So in essence, there’s a detargeting mutation in something called the vesicular stomatitis viral glycoprotein, which is the mechanism by which gene therapy usually works by binding onto the LDL receptor. So despite mutating that, it preserves a high transduction efficiency, but then retargets the virus to the CD3 T-cells using a single-chain variable fragment...
KLN-1010 is an in-vivo CAR-T, which basically utilizes the injection of a modified lentiviral vector, which has a modified envelope. So in essence, there’s a detargeting mutation in something called the vesicular stomatitis viral glycoprotein, which is the mechanism by which gene therapy usually works by binding onto the LDL receptor. So despite mutating that, it preserves a high transduction efficiency, but then retargets the virus to the CD3 T-cells using a single-chain variable fragment. And by doing so, it delivers an anti-BCMA CAR, so that’s the chimeric antigen receptor, to the T-cells. So as it were, we are making the CAR T-cells in vivo. And the advantages of that are that it’s off-the-shelf. It simplifies the logistics. Therefore, we are likely to expand the access. But there’s one possible scientific advantage as well, because the T-cells don’t have to be manipulated in the lab, and therefore they’re likely to be fitter and less exhausted, for instance.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
